Business Wire

Intersolar Europe: How About Some More?

Share

The German government’s goal is to have an equal share of large-scale power plants and roof-mounted systems. In 2023, the large-scale ground-mounted segment was able to increase by 45 percent. With the adoption of Solar Package I, this segment will continue to grow. The package of measures aims to reduce the red tape associated with solar deployment in order to achieve an annual growth of 22 gigawatt peak from 2026. The latest applications, products and business models for large-scale PV power plants will be on display at Intersolar Europe, the world’s leading exhibition for the solar industry. It will be held in Munich from June 19–21 as part of The smarter E Europe, the continent’s largest alliance of exhibitions for the energy industry. Some 3,000 exhibitors and over 115,000 visitors from all corners of the globe are expected to attend. The event will take place across 19 exhibition halls and an Outdoor Area.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240529516051/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Intersolar Europe presents innovations in the field of hybrid systems. (© Solar Promotion GmbH)

Hybrid power plants consisting of PV and wind power or storage, or both, offer various benefits: Sun and wind complement each other’s generation profiles and can be combined in a system, making optimal use of energy infrastructure such as interconnection points and the space required to implement the system. The combination with energy storage comes with additional advantages: It can smooth out the volatility of renewables, and the stored electricity can be fed into the grid when it is needed – or it can be traded for a profit. Energy arbitrage enables the targeted provision and marketing of solar and wind energy on the energy exchange. The electricity is stored when the price is low or a lot of renewable electricity is being produced. When it is profitable to sell the stored electricity, it is fed into the grid.

The latest technologies in operation and maintenance

Artificial intelligence (AI) is all the rage right now. It is also increasingly being used in the solar industry, especially in operations and maintenance (O&M). The AI-driven detection and analysis of incidents and deviations in operations and the standardized creation and selection of tickets are processes in which AI can be used to quickly process large amounts of data. In O&M, AI helps free up human resources for more complex tasks and standardize operations. What’s more, AI-supported software solutions can process weather data and create generation forecasts.

Special solar systems: parking lot PV, agricultural PV and floating PV

With Solar Package I, the “special solar systems” defined in the German Renewable Energy Sources Act EEG now have their own tender segment. These applications are becoming more prevalent and dual land use concepts are coming to the forefront of solar deployment plans. The maximum value for tenders has been raised to 9.5 cents/kWh. The products in this segment are rapidly evolving: carport substructures, elevated vertical and horizontal solar technology with and without trackers for agricultural PV, and mounting solutions for floating PV.

Intersolar Europe

As the world’s leading exhibition for the solar industry, Intersolar Europe demonstrates the enormous vitality of the solar market. For more than 30 years, it has been providing a networking opportunity for key players, focusing on the latest trends, developments and business models under the motto “Connecting Solar Business”. Intersolar Europe will take place from June 19–21, 2024 as part of The smarter E Europe at Messe München.

For more information, please visit: www.intersolar.de.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Roberto Freiberger
ressourcenmangel an der Panke GmbH
Schlesische Straße 26/c4
10997 Berlin
roberto.freiberger@ressourcenmangel.de

Peggy Zilay
Solar Promotion GmbH
P.O. Box 100 170
75101 Pforzheim
zilay@solarpromotion.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye